Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials

Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials Abstract The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta‐analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo‐controlled trials fulfilled pre‐set criteria for high quality and were included in the meta‐analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy‐five per cent of the patients experienced diarrhoea‐predominant IBS and 93% were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 (95% confidence interval (CI) 1.57–2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95% CI 5.74–9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non‐constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurogastroenterology & Motility Wiley

Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials

Loading next page...
 
/lp/wiley/efficacy-of-alosetron-in-irritable-bowel-syndrome-a-meta-analysis-of-dwLeJfzoZY
Publisher
Wiley
Copyright
Copyright © 2003 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1350-1925
eISSN
1365-2982
DOI
10.1046/j.1365-2982.2003.00389.x
Publisher site
See Article on Publisher Site

Abstract

Abstract The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta‐analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo‐controlled trials fulfilled pre‐set criteria for high quality and were included in the meta‐analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy‐five per cent of the patients experienced diarrhoea‐predominant IBS and 93% were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 (95% confidence interval (CI) 1.57–2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95% CI 5.74–9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non‐constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients.

Journal

Neurogastroenterology & MotilityWiley

Published: Feb 1, 2003

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off